Evidence summaries in diabetes, endocrinology, and metabolism for clinicians who need the key data fast.
In a Diabetes Care randomized trial, Sleep-Opt did not improve glycemic targets or sleep parameters, although sleep improved in both intervention groups. Key reported results included A1C and CGM parameters at 12 weeks indicated no significant differences between groups.
In a Diabetes Care randomized trial, A 3-year technology-enhanced, multicomponent program improved cardiometabolic status, proxies of β-cell function, and PROMs in individuals with YOD but did not reduce complications. Key reported results included During 2020 to 2021, 884 participants (mean [SD]...
In a JAMA randomized trial, The authors' conclusion is reported in the source abstract. Key reported results included This predefined subgroup included 3655 patients (1849 in the evolocumab group and 1806 in the placebo group) with a median age of 65 years (57% female).
In a Diabetes Care randomized trial, Using URLi in conventional CSII pump therapy provides more effective BRRs prior to exercise compared with lispro, with fewer hypoglycemic events in active adults with type 1 diabetes. Key reported results included Twenty-five participants (mean ± SD age 36.7 ±...
In a Diabetes Care randomized trial, Semaglutide significantly improved insulin sensitivity, reduced insulin resistance, lowered fasting glucose, and promoted substantial weight loss in patients with antipsychotic-induced metabolic disturbances. Key reported results included Participants (56%...
In a Diabetes Care randomized trial, The Diabetes Body Project produced significantly larger acute effects with small to medium effect sizes compared with educational controls and has potential for broad implementation. Key reported results included Compared with educational controls (n = 146)...
In a Diabetes Care randomized trial, The study's glucose management approach using CGM did not improve glucose levels compared with standard glucose management in the non-intensive care unit hospital setting. Key reported results included For the 110 participants included in the primary analysis...
In a J Clin Endocrinol Metab randomized trial, Treatment with ROMO significantly increased lumbar spine BMD in glucocorticoid-treated patients, suggesting that ROMO is effective for GIOP. Key reported results included Eleven patients were assigned to the ROMO group, 14 to the DMAb group, and 14 to...
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
